Oral florid papillomatosis is a type of verrucous carcinoma (VC) that is clinically evident as multiple squamous papillary nodules in the oral cavity and, less commonly, in the larynx, the pharynx, the esophagus, the middle ear, the maxillary antrum, the nasal fossa, and the bronchus. Verrucous carcinoma usually appears in 3 main sites: the oropharynx, the genital tract, and the soles of the feet. However, verrucous carcinoma can also occur on the cutaneous surface. Accordingly, verrucous carcinoma is known by a number of names.
Oral florid papillomatosis is best defined as a type of verrucous carcinoma, although some consider it a separate entity. Still others consider it a disease on a continuum between viral warts and verrucous carcinoma, rather than a verrucous carcinoma per se.  Lauren V. Ackerman  described oral verrucous carcinoma and coined the term verrucous carcinoma. Oral, laryngeal, pharyngeal, and esophageal lesions of this type are generally known as a verrucous carcinoma or an Ackerman tumor.
Although the term verrucous carcinoma followed by its anatomical site would be the most comprehensive name, the historical name justifiably favors honoring 2 eminent physicians, Abraham Buschke (1868-1943) of Berlin and Ackerman (1905-1993). Buschke was a legendary professor of dermatology, and Ackerman, the renowned professor of pathology, developed the concept of verrucous carcinoma. However, the descriptive name oral florid papillomatosis is also used.
In recent years, the term multifocal papillomavirus epithelial hyperplasia has been used to define the variant that usually occurs in childhood; this variant is characterized by diffuse confluent papillomatous lesions in the oral mucosa. 
In 1934, Kren et al  observed condylomatous neoplasms of the tongue, the palate, and the uvula. In 1941, Friedell and Rosenthal  described verrucous tumors of the buccal mucosa and the lower gingivae in 8 patients who chewed tobacco; these lesions developed in the area in which the quid of tobacco was held. Verrucous carcinoma can affect various oroaerodigestive sites, including the esophagus,  the middle ear,  the maxillary antrum, [8, 9] the nasal fossa,  the lacrimal duct,  and the bronchus. 
Verrucous carcinoma of both the skin and the mucosa is an uncommon low-grade squamous cell carcinoma that is clinically evident as a slowly but relentlessly enlarging warty tumor, histologically characterized by local invasion with minimal dysplasia, if any, and biologically characterized by a low incidence of metastases.  Even when the tumor is large, when it has been present for many years, and when it penetrates the bone, distant metastases are rare.
The typical microscopic section shows a well-differentiated typical squamous cell carcinoma with verrucous clinical morphology.  Ackerman initiated the clinicopathologic concept of verrucous carcinoma and described similar neoplasms of the oral cavity in 31 patients; Ackerman used the term verrucous carcinoma to denote the concept of a locally aggressive exophytic low-grade squamous cell carcinoma with little metastatic potential.  This tumor has also been known as florid papillomatosis, a term Rock and Fisher  coined in 1960. They observed multiple confluent nodules of the oral cavity and the larynx in 3 patients. In 1962, Wechsler and Fisher  emphasized the locally aggressive but clinically benign nature of the disease by using the term oral florid papillomatosis.
The 4 clinicopathologic types of verrucous carcinoma are as follows: (1) the anourogenital type, which includes giant condyloma acuminatum, Buschke-Löwenstein tumor, giant malignant condyloma, verrucous carcinoma of the anogenital mucosa, carcinomalike condyloma, and condylomatoid precarcinosis; (2) the oroaerodigestive type, which includes the Ackerman tumor, verrucous carcinoma of Ackerman, and oral florid papillomatosis; (3) the foot type, epithelioma cuniculatum; and (4) other cutaneous types, which include cutaneous verrucous carcinoma, papillomatosis cutis carcinoides, and papillomatosis cutis.
Oral verrucous carcinoma should be recognized as an important clinicopathologic variant of squamous cell carcinoma. Its apparent clinical benignity may result in lengthy periods of misdiagnosis, during which it is not likely to spread to distant lymph nodes. Instead, oral verrucous carcinoma is more likely to destroy the nose or the mandible as it slowly but relentlessly extends into the underlying tissue, following what appears to be the path of least resistance that often causes it to develop around regional lymph nodes and not directly involve them. To those unfamiliar with oral verrucous carcinoma, its morphologic warty or verrucous appearance and its relatively bland histologic features often suggest verruca vulgaris or pseudoepitheliomatous hyperplasia rather than squamous cell carcinoma. When the lesion extends into underlying tissues, it may occasionally be mistaken for a benign adnexal tumor or rarely an epidermoid cyst at histologic examination.
Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma was found to correlate with lack of histological differentiation.  An exploration of nuclear expression of cyclin B1 suggested overexpression is salient in early carcinogenesis, cell differentiation, and tumor proliferation. 
Human papillomavirus infection may or may not play a role in dysplastic and malignant oral verrucous lesions.  There has been a wide range in the incidence of virus detection.
Many people worldwide use smokeless tobacco, a habit strongly linked with both squamous cell carcinoma and verrucous carcinoma.  For those who chew tobacco, the oral cancer appears at the site of tobacco placement, the gingivobuccal sulcus. 
Oral verrucous carcinoma is a rare neoplasm that occurs in older people. It is diagnosed in only 1-3 of every 1 million persons each year.  The age-adjusted average annual incidence for oral verrucous carcinoma among residents of Rochester, Minnesota, was 0.1 case per 100,000 person-years (0.2 for males, 0.0 for females), whereas the incidence for all intraoral carcinomas was 3.6 cases per 100,000 person-years (5.4 for males, 2.1 for females).
The Ackerman tumor represents 2-12% of all oral carcinomas. [22, 23, 24, 25] In men older than 64 years, the incidence increases to 3.2 cases per 100,000 person-years; the lesion represented only 3% of the oral cancers. 
Oral verrucous carcinoma is a rare neoplasm (see Frequency, United States, above). Verrucous carcinoma represents about 400 (5%) of 7988 primary malignancies of the oral cavity in India,  with most occurring in persons aged 40-50 years or older. 
A male predisposition is usually observed, although in one study, almost 60% of cases occurred in women.  In his original series, Ackerman documented 31 cases, 26 of which involved men. Although most patients (60.0%) are men, tumors of the oral cavity are more common among older females, according to the National Cancer Data Base, which includes data on 2350 cases of verrucous carcinoma of the head and the neck.  Verrucous carcinoma of the larynx is more common in men than in women. [26, 27]
In Ackerman's original series, the average patient age was 67 years. In another survey, most patients were aged 40-50 years or older.  Most patients with verrucous carcinoma of the larynx are older than 60 years. [26, 27]
These tumors often cause considerably more morbidity than mortality.
The National Cancer Data Base includes 2350 cases of verrucous carcinoma of the head and the neck.  Most verrucous carcinomas originate in the oral cavity (55.9%) and the larynx (35.2%), and the 5-year relative survival rate is 77.9%. For localized verrucous carcinoma, the survival rate after surgery is 88.9% compared with 57.6% after irradiation. Patients receiving initial surgical treatment have a better survival rate than those treated with irradiation, especially if their lesions originated in the oral cavity.
Three hundred and two patients with oral verrucous carcinoma in India were evaluated retrospectively.  Early-stage tumors accounted for 39.7%; 60.4% were late-stage tumors. Sixty-eight percent (19 of 28) recurred locally; the salvage rate for recurrent tumors was 66.7% (16 of 28), with a median post-recurrence survival of 16 months (range, 10-83 mo). The 5-year disease-free survival rate after surgical therapy was 77.6%. Another study found a 5-year survival rate of about 50%.